2020 Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent. Blood February 2020.

2016 Podust V.N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. Journal of Controlled Release 240: 52-66.

2016 Moore W.V. et al. A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency. The Journal of Clinical Endocrinology and Metabolism 101(3):1091-1097.

2014 Ding S. et al. Multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility. Bioconjugate Chemistry 25(7):1351-1359.

2013 Podust V.N. et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Engineering, Design & Selection 26(11):743-753.

2013 Yuen K.C.J. et al. A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults. The Journal of Clinical Endocrinology and Metabolism 98(6):2595-2603.

2012 Alters S.E. et al. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s disease model. PLoS ONE 7(11):e50630.

2012 Cleland J.L. et al. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life. Journal of Pharmaceutical Sciences 101(8):2744-2754.

2010 Geething N.C. et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE 5(4):e10175.

2009 Schellenberger V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nature Biotechnology 27(12):1186-1190.